Insulet (NASDAQ:PODD) Rating Lowered to “Hold” at Zacks Research

Insulet (NASDAQ:PODD) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

PODD has been the subject of a number of other research reports. Leerink Partners boosted their price objective on Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. BTIG Research boosted their price target on Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a research note on Friday, November 21st. Wells Fargo & Company upped their price objective on Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a report on Friday, November 7th. JPMorgan Chase & Co. increased their price objective on Insulet from $340.00 to $415.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Finally, Raymond James Financial boosted their target price on shares of Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a research report on Friday, November 21st. Twenty-one equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $381.75.

Insulet Trading Up 3.8%

PODD stock opened at $294.35 on Monday. Insulet has a one year low of $230.05 and a one year high of $354.88. The stock has a market cap of $20.71 billion, a price-to-earnings ratio of 85.32, a price-to-earnings-growth ratio of 1.58 and a beta of 1.40. The company has a fifty day moving average price of $308.15 and a two-hundred day moving average price of $312.15. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. Insulet’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.08 EPS. Equities analysts anticipate that Insulet will post 3.92 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PODD. True Wealth Design LLC grew its stake in Insulet by 288.0% during the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares in the last quarter. Kozak & Associates Inc. bought a new stake in shares of Insulet during the 2nd quarter worth approximately $32,000. Golden State Wealth Management LLC boosted its position in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH bought a new position in Insulet in the second quarter valued at approximately $35,000. Finally, Whittier Trust Co. of Nevada Inc. raised its position in Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 43 shares in the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.